

**From:** [Home, Christine](#)  
**To:** [Home, Christine](#)  
**Subject:** RE: Counterfeit discovery reporting  
**Date:** Tuesday, October 11, 2022 4:20:10 PM  
**Attachments:** [image001.png](#)  
[image002.png](#)

---

---

**From:** Michael Crow, Esq. <[michael.crow@pharma.solutions](mailto:michael.crow@pharma.solutions)>  
**Sent:** Thursday, September 29, 2022 9:12 AM  
**To:** OPLC: Customer Support <[customersupport@opl.nh.gov](mailto:customersupport@opl.nh.gov)>  
**Subject:** Counterfeit discovery reporting

**EXTERNAL:** Do not open attachments or click on links unless you recognize and trust the sender.

---

Hello Regulators:

I have reviewed the New Hampshire regulations and statutes. I have also reviewed your agency website in attempt to determine what notification steps, if any, must be taken by Distributors or Manufacturers who discover counterfeit product in their possession. Some states defer to the Federal procedure. Some states require their licensees to report directly to them.

Can you advise what is the proper procedure in your jurisdiction? Is reporting to the FDA proper, or must the State Board of Pharmacy also be advised in all cases?

Is this applicable for all products: Prescription/Legend, Controlled Substance, and Over the Counter? Also, do these requirements apply only to product likely to enter New Hampshire? Or if a New Hampshire licensee discovers product anywhere in their commerce stream?

Any guidance or help you can offer would be appreciated.  
My thanks in advance.

Sincerely,

Michael Crow

Michael Crow, Esq.  
Compliance Attorney  
Email: [michael.crow@pharma.solutions](mailto:michael.crow@pharma.solutions)

office: (484) 800-1863 ext 206  
direct: (610) 934-2319

LinkedIn



This email may be confidential and privileged. If you have received this communication in error, please do not forward it to anyone else, please erase all copies and attachments, and please let me know that it has gone to the wrong person. The above terms may reflect a potential business arrangement, are provided solely as a basis for further discussion, and are not intended to be and do not constitute a legally binding obligation. No legally binding obligations will be created, implied, or inferred until an agreement in final form is executed in writing by all parties involved.